Hoofdmenu
Over Forces...
Thema's
Posters
Media
Vliegen
Links
Forces NL Forum
Discussies
Commentaren
Steun Forces
Archief
Horror Stories
Artikelen
Analyses
Navigatie
Hoofdpagina
Terug
Internationaal
Forces Psychiatry
Canada
Toronto
Manitoba (email)
Italy
New Zealand
UK (email)
Russia
VS afdelingen
California
Connecticut
Delaware
Duluth
Georgia
Indiana
Maine
Massachusetts
Minnesota
Rochester
USA
Virginia
Affiliates
Smokers' Club
NYC C.L.A.S.H.
Smoking Paradise
MA Citizens for
Freedom
Real Texas Freedom
Ontario Smoking
Forces Comité
van Aanbeveling
Forces Nederland
E-Mail:
info@forces-nl.org
| |
Researcher Sees Possible Prozac Cancer Link
LONDON (Reuters) - Prozac and related antidepressants could in theory
increase the risk of brain cancer by preventing the body's innate ability to
kill tumor cells, a British researcher said Tuesday.
- 2002/03/26
Professor John Gordon of Birmingham University reported that Prozac and other
selective serotonin reuptake inhibitors (SSRIs) encouraged growth of a type of
cancer called Burkitt's lymphoma in test-tube experiments. While there is no
evidence from clinical trials on people to back up the concerns, the finding is
likely to reopen controversy about the widespread use of the class of
antidepressants that first went on sale in the 1980s. Millions of people with
depression and anxiety have been prescribed the drugs, which have emerged as one
of the biggest sellers for the international pharmaceutical industry.
Gordon, whose findings were published in the online edition of the medical
journal Blood, said serotonin was a key driver in stimulating apoptosis, a
natural cell "suicide" process for controlling the runaway growth that leads to
cancer.
SSRIs such as Eli Lilly and Co.'s Prozac, Glaxo SmithKline Plc's Paxil and
Lundbeck's Celexa, however, appear to block this action. Drug company officials
said there was no evidence that their pills caused any increase of cancer in
practice and questioned whether the high doses used in Gordon's experiments may
have been responsible for the results.
"These data are from an in vitro (test tube) study and as such they cannot be
extrapolated to a clinical setting with any degree of certainty," said Martin
Sutton, a spokesman for GSK. Paxil, which is also known as Seroxat, has
overtaken Prozac as the world's best-selling SSRI with worldwide sales last year
of $2.7 billion.
|
Zend
deze pagina naar een vriend